2 results match your criteria: "a Jiangsu Provincial Center for Diseases Control and Prevention[Affiliation]"
One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study.
Hum Vaccin Immunother
June 2019
b Lanzhou Institute of Biological Products Co.,Ltd. , Lanzhou , China.
Background: To evaluate the one-year immunogenicity and safety of a subunit plague vaccine.
Methods: In the initial study, 240 healthy adults aged 18-55 years were administrated with 2 doses of 15 or 30 µg plague vaccines at day 0 and 28, respectively. In this extended follow-up study, we evaluated the immunogenicity and safety of the plague vaccine up to one year.
Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial.
Hum Vaccin Immunother
September 2016
a Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing , China.
Background: Although the killed whole-cell and live attenuated plague vaccine have been licensed, they are rarely used today because of toxicities, limited evidence of efficacy against plague, poor immune persistence required booster immunization every year, and limited commercial availability. This study was a randomized phase 2a clinical trial aimed to evaluating the immunogenicity and safety of a novel subunit plague vaccine.
Methods: 240 healthy adults aged 18-55 y were enrolled and randomly assigned at a ratio of 1:1 to receive 2 doses of 15 or 30 mcg vaccine at a 28-day interval between doses.